Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
National Cancer Institute (NCI)
BioNTech SE
Bristol-Myers Squibb
Canadian Cancer Trials Group
AbbVie
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Henlius Biotech
Bristol-Myers Squibb
NRG Oncology
Cancer Research UK
AbbVie